ClinicalTrials.gg
CompletedNCT03011892Updated Apr 9, 2021Results posted

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

A Phase 2 interventional study of Ruxolitinib 0.15% Cream QD and Ruxolitinib 0.5% Cream QD in Atopic Dermatitis, sponsored by Incyte Corporation. Completed at 52 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-04-09.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
307
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing ruxolitinib in Dermatitis, Atopic — 2 open to participants now, 3 under way, 1 of them phase 3. ruxolitinib · Dermatitis, Atopic.

Enrollment
4th of 15
307 · median 77
Started
2017
with 1 other
Phase 2
3 of 15
none open now
Registered
1st of 15
by date
Lead sponsor
13 of 15
Incyte Corporation

Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, this one is the 4th largest by enrollment, is one of 2 that started in 2017, is one of 3 in phase 2, and was the 1st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 15 studies testing ruxolitinib in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ruxolitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this study is to establish the efficacy of each strength of ruxolitinib cream once daily (QD) or twice daily (BID) in participants with atopic dermatitis as compared with vehicle cream BID.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Atopic dermatitis
  • eczema
  • pruritus
  • Janus kinase (JAK) inhibitors
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants diagnosed with atopic dermatitis (AD) as defined by the Hanifin and Rajka criteria.
  • Participants with a history of AD for at least 2 years.
  • Participants with an Investigator's Global Assessment (IGA) score of 2 to 3 at screening and baseline.
  • Participants with body surface area (BSA) of AD involvement, excluding the face and intertriginous areas, of 3% to 20% at screening and baseline.
  • Participants who agree to discontinue all agents used to treat AD from screening through the final follow-up visit.

Exclusion criteria

Exclusion Criteria:

  • Participants with evidence of active acute or chronic infections.
  • Use of topical treatments for AD (other than bland emollients) within 2 weeks of baseline.
  • Systemic or immunomodulating drugs (eg, oral or injectable , methotrexate, cyclosporine, mycophenolate mofetil, azathioprine) within 4 weeks or 5 half-lives of baseline (whichever is longer).
  • Participants with other dermatologic disease besides AD whose presence or treatments could complicate the assessment of disease (eg, psoriasis).
  • Participants with a history of other diseases besides dermatologic disorders (eg, other diseases) taking treatments that could complicate assessments.
  • Participants with cytopenias at screening, defined as:

    • Leukocytes \< 3.0 × 10\^9/L.
    • Neutrophils \< lower limit of normal.
    • \< 10 g/dL.
    • Lymphocytes \< 0.8 × 10\^9/L
    • \< 100 × 10\^9/L.
  • Participants with severely impaired liver function ( Class C) or end-stage renal disease (ESRD) on dialysis or at least 1 of the following:

    • Serum creatinine > 1.5 mg/dL.
    • (ALT) or aspartate aminotransferase (AST) ≥ 1.5 × .
  • Participants taking potent systemic cytochrome P450 3A4 inhibitors or fluconazole within 2 weeks or 5 half-lives, whichever is longer, before the baseline visit (topical agents with limited systemic availability are permitted).
  • Participants who have previously received Janus kinase (JAK) inhibitors, systemic or topical (e.g., ruxolitinib, tofacitinib, baricitinib, filgotinib, lestaurtinib, pacritinib).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
307 participants (actual)

Study arms

  • Placebo comparator
    Double Blind (DB): Vehicle BID

    Participants applied vehicle cream twice daily (BID) for 8 weeks DB period.

    Drug: Vehicle Cream BID

  • Active comparator
    DB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BID

    Participants applied triamcinolone 0.1% cream BID for 4 weeks followed by vehicle cream for 4 weeks in DB period.

    Drug: Triamcinolone 0.1% Cream BID · Drug: Vehicle Cream BID

  • Experimental
    DB: Ruxolitinib 0.15% Once Daily (QD)

    Participants applied ruxolitinib 0.15% cream QD for 8 weeks in DB period.

    Drug: Ruxolitinib 0.15% Cream QD

  • Experimental
    DB: Ruxolitinib 0.5% QD

    Participants applied ruxolitinib 0.5% cream QD for 8 weeks in DB period.

    Drug: Ruxolitinib 0.5% Cream QD

  • Experimental
    DB: Ruxolitinib 1.5% QD

    Participants applied ruxolitinib 1.5% cream QD for 8 weeks in DB period.

    Drug: Ruxolitinib 1.5% Cream QD

  • Experimental
    DB: Ruxolitinib 1.5% BID

    Participants applied ruxolitinib 1.5% cream BID for 8 weeks in DB period.

    Drug: Ruxolitinib 1.5% Cream BID

  • Placebo comparator
    Open-Label (OL): Vehicle BID to Ruxolitinib 1.5% BID

    Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.

    Drug: Ruxolitinib 1.5% Cream BID

  • Active comparator
    OL: TAC BID/Vehicle BID to Ruxolitinib 1.5% BID

    Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.

    Drug: Ruxolitinib 1.5% Cream BID

  • Experimental
    OL: Ruxolitinib 0.15% QD to Ruxolitinib 1.5% BID

    Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.

    Drug: Ruxolitinib 1.5% Cream BID

  • Experimental
    OL: Ruxolitinib 0.5% QD to Ruxolitinib 1.5% BID

    Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.

    Drug: Ruxolitinib 1.5% Cream BID

  • Experimental
    OL: Ruxolitinib 1.5% QD to Ruxolitinib 1.5% BID

    Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.

    Drug: Ruxolitinib 1.5% Cream BID

  • Experimental
    OL: Ruxolitinib 1.5% BID to Ruxolitinib 1.5% BID

    Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.

    Drug: Ruxolitinib 1.5% Cream BID

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Percentage Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4 in Participants Treated With Ruxolitinib 1.5% Cream Twice a Day (BID) Compared With Participants Treated With Vehicle Cream BID

    EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.

    Time frame: Baseline and Week 4

Secondary outcomes

  1. Mean Percentage Change From Baseline in EASI Score at Week 4 in Participants Treated With Ruxolitinib QD Compared With Participants Treated With Vehicle Cream BID

    EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.

    Time frame: Baseline and Week 4

  2. Mean Percentage Change From Baseline in EASI Score at Week 4 in Participants Treated With Ruxolitinib QD/BID Cream Compared With Participants Treated With Triamcinolone 0.1% Cream BID Followed by Vehicle

    EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.

    Time frame: Baseline and Week 4

  3. Mean Percentage Change From Baseline in EASI Score at Week 2 and Week 8

    EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.

    Time frame: Baseline, Week 2 and 8

  4. Percentage of Participants Who Achieve a ≥ 50% Improvement From Baseline in EASI (EASI-50) at Weeks 2, 4, and 8

    The categorical variable EASI-50 will be equal to 1 for percentage improvement from baseline in EASI score of 50% or greater and will be equal to 0 for percentage improvement of less than 50%. This definition is introduced for the purpose of identifying participants who respond to the treatment (1 = responder, 0 = non-responder).

    Time frame: Week 2, 4 and 8

  5. Percentage Change From Baseline in EASI Score at Week 4

    EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.

    Time frame: Baseline and Week 4

  6. Time to Achieve EASI-50

    Time to EASI-50 is defined as the interval between the time of randomization and the time of achieving at least 50% improvement in EASI score.

    Time frame: From Baseline to Week 8

  7. Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 to 1 Who Have an Improvement of ≥ 2 Points From Baseline at Weeks 2, 4, and 8

    IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). An IGA responder was defined as a participant achieving an IGA score of 0 to 1 and an IGA score improvement at least 2 from baseline.

    Time frame: Week 2, 4 and 8

  8. Mean Change From Baseline in the Itch Numerical Rating Scale (NRS) Score at Weeks 2, 4, and 8

    The Itch NRS is a once-per-24 hours ("daily") participant-reported measure of itch intensity to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The categorical NRS is defined as 0 = None, 1 to 3 = Mild, 4 to 6 = Moderate, and 7 to 10 = Severe.

    Time frame: Baseline, Week 2, 4 and 8

  9. Number of Participants With At Least One Adverse Event (AEs) and as Per Severity

    AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4.Data are reported for Grade 3 and higher severity for this outcome measure.

    Time frame: Up to Week 24

07

Results

Posted Apr 9, 2021

Participant flow

A total of 307 participants were randomized and 306 were treated at 50 study centers in the United States and Canada from 9 January 2017 to 12 March 2018.

Double Blind (DB) Period
Participant flow — Double Blind (DB) Period
MilestoneDouble Blind (DB): Vehicle BIDDB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BIDDB: Ruxolitinib 0.15% Once Daily (QD)DB: Ruxolitinib 0.5% QDDB: Ruxolitinib 1.5% QDDB: Ruxolitinib 1.5% BIDOpen-Label (OL): Vehicle BID to Ruxolitinib 1.5% BIDOL: TAC BID/ Vehicle BID to Ruxolitinib 1.5% BIDOL: Ruxolitinib 0.15% QD to Ruxolitinib 1.5% BIDOL: Ruxolitinib 0.5% QD to Ruxolitinib 1.5% BIDOL: Ruxolitinib 1.5% QD to Ruxolitinib 1.5% BIDOL: Ruxolitinib 1.5% Cream BID for 8 Weeks in DB Period.
Started525151515250000000
Treated in db period525151515150000000
Completed treatment through week 4444648474949000000
Completed414145444545000000
Not completed11106775000000
Withdrew: Adverse event011000000000
Withdrew: Lack of efficacy100000000000
Withdrew: Lost to follow-up032502000000
Withdrew: Other111010000000
Withdrew: Physician decision101000000000
Withdrew: Pregnancy000010000000
Withdrew: Protocol violation100000000000
Withdrew: Withdrawal by subject751243000000
Withdrew: Randomized but not treated000010000000
Open Label (OL) Period
Participant flow — Open Label (OL) Period
MilestoneDouble Blind (DB): Vehicle BIDDB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BIDDB: Ruxolitinib 0.15% Once Daily (QD)DB: Ruxolitinib 0.5% QDDB: Ruxolitinib 1.5% QDDB: Ruxolitinib 1.5% BIDOpen-Label (OL): Vehicle BID to Ruxolitinib 1.5% BIDOL: TAC BID/ Vehicle BID to Ruxolitinib 1.5% BIDOL: Ruxolitinib 0.15% QD to Ruxolitinib 1.5% BIDOL: Ruxolitinib 0.5% QD to Ruxolitinib 1.5% BIDOL: Ruxolitinib 1.5% QD to Ruxolitinib 1.5% BIDOL: Ruxolitinib 1.5% Cream BID for 8 Weeks in DB Period.
Started000000414045414243
Completed000000343743414040
Not completed000000732023
Withdrew: Lost to follow-up000000421011
Withdrew: Withdrawal by subject000000301012
Withdrew: Reason not specified000000010000

Outcome measures

PrimaryMean Percentage Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4 in Participants Treated With Ruxolitinib 1.5% Cream Twice a Day (BID) Compared With Participants Treated With Vehicle Cream BID

EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · percent change
Mean Percentage Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4 in Participants Treated With Ruxolitinib 1.5% Cream Twice a Day (BID) Compared With Participants Treated With Vehicle Cream BID
percent changeDB: Vehicle BIDDB: Ruxolitinib 1.5% BID
Mean Percentage Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4 in Participants Treated With Ruxolitinib 1.5% Cream Twice a Day (BID) Compared With Participants Treated With Vehicle Cream BID-11.90 ± 6.65-71.57 ± 6.42
Statistical analysis
  • DB: Vehicle BID vs DB: Ruxolitinib 1.5% BID · MMRM · p = < 0.0001 · Difference in least square (ls) mean: -59.66 · 95% CI -77.85 to -41.47
SecondaryMean Percentage Change From Baseline in EASI Score at Week 4 in Participants Treated With Ruxolitinib QD Compared With Participants Treated With Vehicle Cream BID

EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · percent change
Mean Percentage Change From Baseline in EASI Score at Week 4 in Participants Treated With Ruxolitinib QD Compared With Participants Treated With Vehicle Cream BID
percent changeDB: Vehicle BIDDB: Ruxolitinib 0.15% QDDB: Ruxolitinib 0.5% QDDB: Ruxolitinib 1.5% QD
Mean Percentage Change From Baseline in EASI Score at Week 4 in Participants Treated With Ruxolitinib QD Compared With Participants Treated With Vehicle Cream BID-11.90 ± 6.65-44.92 ± 6.47-52.80 ± 6.52-66.72 ± 6.36
Statistical analysis
  • DB: Vehicle BID vs DB: Ruxolitinib 0.15% QD · MMRM · p = 0.0004 · Difference in ls mean: -33.01 · 95% CI -51.27 to -14.76
  • DB: Vehicle BID vs DB: Ruxolitinib 0.5% QD · MMRM · p = < 0.0001 · Difference in ls mean: -40.90 · 95% CI -59.23 to -22.57
  • DB: Vehicle BID vs DB: Ruxolitinib 1.5% QD · MMRM · p = < 0.0001 · Difference in ls mean: -54.82 · 95% CI -72.93 to -36.70
SecondaryMean Percentage Change From Baseline in EASI Score at Week 4 in Participants Treated With Ruxolitinib QD/BID Cream Compared With Participants Treated With Triamcinolone 0.1% Cream BID Followed by Vehicle

EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · percent change
Mean Percentage Change From Baseline in EASI Score at Week 4 in Participants Treated With Ruxolitinib QD/BID Cream Compared With Participants Treated With Triamcinolone 0.1% Cream BID Followed by Vehicle
percent changeDB: TAC 0.1% BID/Vehicle Cream BIDDB: Ruxolitinib 0.15% QDDB: Ruxolitinib 0.5% QDDB: Ruxolitinib 1.5% QDDB: Ruxolitinib 1.5% BID
Mean Percentage Change From Baseline in EASI Score at Week 4 in Participants Treated With Ruxolitinib QD/BID Cream Compared With Participants Treated With Triamcinolone 0.1% Cream BID Followed by Vehicle-59.54 ± 6.53-44.92 ± 6.47-52.80 ± 6.52-66.72 ± 6.36-71.57 ± 6.42
Statistical analysis
  • DB: TAC 0.1% BID/Vehicle Cream BID vs DB: Ruxolitinib 0.15% QD · MMRM · p = 0.1127 · Difference in ls mean: 14.63 · 95% CI -3.47 to 32.73
  • DB: TAC 0.1% BID/Vehicle Cream BID vs DB: Ruxolitinib 0.5% QD · MMRM · p = 0.4659 · Difference in ls mean: 6.74 · 95% CI -11.44 to 24.92
  • DB: TAC 0.1% BID/Vehicle Cream BID vs DB: Ruxolitinib 1.5% QD · MMRM · p = 0.4320 · Difference in ls mean: -7.18 · 95% CI -25.13 to 10.77
  • DB: TAC 0.1% BID/Vehicle Cream BID vs DB: Ruxolitinib 1.5% BID · MMRM · p = 0.1903 · Difference in ls mean: -12.02 · 95% CI -30.05 to 6.00
SecondaryMean Percentage Change From Baseline in EASI Score at Week 2 and Week 8

EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.

Time frame:
Baseline, Week 2 and 8
Reported as:
Least squares mean · percent change
Mean Percentage Change From Baseline in EASI Score at Week 2 and Week 8
percent changeDB: Vehicle BIDDB: TAC 0.1% BID/Vehicle Cream BIDDB: Ruxolitinib 0.15% QDDB: Ruxolitinib 0.5% QDDB: Ruxolitinib 1.5% QDDB: Ruxolitinib 1.5% BID
Week 2-4.84 ± 5.34-39.94 ± 5.29-29.96 ± 5.23-45.88 ± 5.41-49.88 ± 5.18-52.68 ± 5.29
Week 8-21.86 ± 7.09-58.02 ± 6.94-50.24 ± 6.82-58.37 ± 6.93-67.05 ± 6.72-79.01 ± 6.83
Statistical analysis
  • DB: Vehicle BID vs DB: Ruxolitinib 0.15% QD · MMRM · p = 0.0009 · Difference in ls mean: -25.12 · 95% CI -39.84 to -10.41
  • DB: Vehicle BID vs DB: Ruxolitinib 1.5% BID · MMRM · p = < 0.0001 · Difference in ls mean: -47.85 · 95% CI -62.64 to -33.06
  • DB: Vehicle BID vs DB: Ruxolitinib 0.5% QD · MMRM · p = < 0.0001 · Difference in ls mean: -41.04 · 95% CI -56.00 to -26.08
  • DB: Vehicle BID vs DB: Ruxolitinib 1.5% QD · MMRM · p = < 0.0001 · Difference in ls mean: -45.05 · 95% CI -59.69 to -30.40
  • DB: TAC 0.1% BID/Vehicle Cream BID vs DB: Ruxolitinib 0.15% QD · MMRM · p = 0.1806 · Difference in ls mean: 9.99 · 95% CI -4.66 to 24.63
  • DB: TAC 0.1% BID/Vehicle Cream BID vs DB: Ruxolitinib 0.5% QD · MMRM · p = 0.4333 · Difference in ls mean: -5.93 · 95% CI -20.82 to 8.95
  • DB: TAC 0.1% BID/Vehicle Cream BID vs DB: Ruxolitinib 1.5% QD · MMRM · p = 0.1805 · Difference in ls mean: -9.94 · 95% CI -24.51 to 4.63
  • DB: TAC 0.1% BID/Vehicle Cream BID vs DB: Ruxolitinib 1.5% BID · MMRM · p = 0.0895 · Difference in ls mean: -12.74 · 95% CI -27.45 to 1.98
  • DB: Vehicle BID vs DB: Ruxolitinib 0.15% QD · MMRM · p = 0.0042 · Difference in ls mean: -28.38 · 95% CI -47.74 to -9.02
  • DB: Vehicle BID vs DB: Ruxolitinib 0.5% QD · MMRM · p = 0.0003 · Difference in ls mean: -36.52 · 95% CI -56.03 to -17.01
  • DB: Vehicle BID vs DB: Ruxolitinib 1.5% QD · MMRM · p = < 0.0001 · Difference in ls mean: -45.19
  • DB: Vehicle BID vs DB: Ruxolitinib 1.5% BID · MMRM · p = < 0.0001 · Difference in ls mean: -57.15 · 95% CI -76.53 to -37.77
  • DB: TAC 0.1% BID/Vehicle Cream BID vs DB: Ruxolitinib 0.15% QD · MMRM · p = 0.4243 · Difference in ls mean: 7.78 · 95% CI -11.37 to 26.93
  • DB: TAC 0.1% BID/Vehicle Cream BID vs DB: Ruxolitinib 0.5% QD · MMRM · p = 0.9715 · Difference in ls mean: -0.35 · 95% CI -19.65 to 18.95
  • DB: TAC 0.1% BID/Vehicle Cream BID vs DB: Ruxolitinib 1.5% QD · MMRM · p = 0.3507 · Difference in ls mean: -9.03 · 95% CI -28.05 to 9.99
  • DB: TAC 0.1% BID/Vehicle Cream BID vs DB: Ruxolitinib 1.5% BID · MMRM · p = 0.0320 · Difference in ls mean: -20.98 · 95% CI -40.15 to -1.82
SecondaryPercentage of Participants Who Achieve a ≥ 50% Improvement From Baseline in EASI (EASI-50) at Weeks 2, 4, and 8

The categorical variable EASI-50 will be equal to 1 for percentage improvement from baseline in EASI score of 50% or greater and will be equal to 0 for percentage improvement of less than 50%. This definition is introduced for the purpose of identifying participants who respond to the treatment (1 = responder, 0 = non-responder).

Time frame:
Week 2, 4 and 8
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a ≥ 50% Improvement From Baseline in EASI (EASI-50) at Weeks 2, 4, and 8
percentage of participantsDB: Vehicle BIDDB: TAC 0.1% BID/Vehicle Cream BIDDB: Ruxolitinib 0.15% QDDB: Ruxolitinib 0.5% QDDB: Ruxolitinib 1.5% QDDB: Ruxolitinib 1.5% BID
Week 213.543.131.457.150.052.0
Week 423.166.752.958.873.178.0
Week 826.960.854.962.769.276.0
SecondaryPercentage Change From Baseline in EASI Score at Week 4

EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.

Time frame:
Baseline and Week 4
Reported as:
Mean · percent change
Percentage Change From Baseline in EASI Score at Week 4
percent changeDB: Vehicle BIDDB: TAC 0.1% BID/Vehicle Cream BIDDB: Ruxolitinib 0.15% QDDB: Ruxolitinib 0.5% QDDB: Ruxolitinib 1.5% QDDB: Ruxolitinib 1.5% BID
Percentage Change From Baseline in EASI Score at Week 4-15.5 ± 65.71-59.8 ± 35.71-45.4 ± 53.96-52.2 ± 48.32-67.0 ± 26.28-71.6 ± 25.27
SecondaryTime to Achieve EASI-50

Time to EASI-50 is defined as the interval between the time of randomization and the time of achieving at least 50% improvement in EASI score.

Time frame:
From Baseline to Week 8
Reported as:
Median · week
Time to Achieve EASI-50
weekDB: Vehicle BIDDB: TAC 0.1% BID/Vehicle Cream BIDDB: Ruxolitinib 0.15% QDDB: Ruxolitinib 0.5% QDDB: Ruxolitinib 1.5% QDDB: Ruxolitinib 1.5% BID
Time to Achieve EASI-504 (0 to 8)2 (0 to 8)4 (0 to 8)2 (0 to 8)2 (0 to 8)2 (0 to 8)
SecondaryPercentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 to 1 Who Have an Improvement of ≥ 2 Points From Baseline at Weeks 2, 4, and 8

IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). An IGA responder was defined as a participant achieving an IGA score of 0 to 1 and an IGA score improvement at least 2 from baseline.

Time frame:
Week 2, 4 and 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 to 1 Who Have an Improvement of ≥ 2 Points From Baseline at Weeks 2, 4, and 8
percentage of participantsDB: Vehicle BIDDB: TAC 0.1% BID/Vehicle Cream BIDDB: Ruxolitinib 0.15% QDDB: Ruxolitinib 0.5% QDDB: Ruxolitinib 1.5% QDDB: Ruxolitinib 1.5% BID
Week 21.911.85.94.113.58.0
Week 47.725.59.813.721.238.0
Week 89.617.615.731.430.848.0
SecondaryMean Change From Baseline in the Itch Numerical Rating Scale (NRS) Score at Weeks 2, 4, and 8

The Itch NRS is a once-per-24 hours ("daily") participant-reported measure of itch intensity to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The categorical NRS is defined as 0 = None, 1 to 3 = Mild, 4 to 6 = Moderate, and 7 to 10 = Severe.

Time frame:
Baseline, Week 2, 4 and 8
Reported as:
Mean · score on scale
Mean Change From Baseline in the Itch Numerical Rating Scale (NRS) Score at Weeks 2, 4, and 8
score on scaleDB: Vehicle BIDDB: TAC 0.1% BID/ Vehicle BIDDB: Ruxolitinib 0.15% QDDB: Ruxolitinib 0.5% QDDB: Ruxolitinib 1.5% QDDB: Ruxolitinib 1.5% BID
Baseline6.0 ± 2.115.2 ± 2.226.1 ± 2.236.2 ± 1.716.2 ± 2.145.9 ± 2.25
Change from Baseline at Week 2-0.7 ± 1.46-2.2 ± 1.75-1.9 ± 1.97-2.5 ± 2.23-3.1 ± 2.14-3.7 ± 2.56
Change from Baseline at Week 4-1.0 ± 1.79-2.5 ± 1.94-2.3 ± 2.08-2.6 ± 2.22-3.3 ± 2.24-4.0 ± 2.89
Change from Baseline at Week 8-1.2 ± 2.13-2.2 ± 1.86-3.0 ± 2.49-2.9 ± 2.41-3.8 ± 2.39-4.2 ± 2.91
SecondaryNumber of Participants With At Least One Adverse Event (AEs) and as Per Severity

AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent. The severity of AEs was assessed using CTCAE v4.03 Grades 1 through 4.Data are reported for Grade 3 and higher severity for this outcome measure.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With At Least One Adverse Event (AEs) and as Per Severity
ParticipantsDB: Vehicle BIDDB: TAC 0.1% BID/Vehicle Cream BIDDB: Ruxolitinib 0.15% QDDB: Ruxolitinib 0.5% QDDB: Ruxolitinib 1.5% QDDB: Ruxolitinib 1.5% BIDOL: Vehicle BID to Ruxolitinib 1.5% BIDOL: TAC BID/Vehicle Cream BID to Ruxolitinib 1.5% BIDOL: Ruxolitinib 0.15% QD to Ruxolitinib 1.5% BIDOL: Ruxolitinib 0.5% QD to Ruxolitinib 1.5% BIDOL: Ruxolitinib 1.5% QD to Ruxolitinib 1.5% BIDOL: Ruxolitinib 1.5% BID
At Least One AE1717191117125111181117
Grade 3 and Higher020101010000

Adverse events

Collected over Up to Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vehicle BID0/52 (0%)0/52 (0%)10/52 (19.2%)
Triamcinolone 0.1% BID for 4 Weeks Then 4 Week Vehicle BID0/51 (0%)1/51 (2%)3/51 (5.9%)
INCB018424 0.15% QD0/51 (0%)0/51 (0%)6/51 (11.8%)
INCB018424 0.5% QD0/51 (0%)0/51 (0%)2/51 (3.9%)
INCB018424 1.5% QD0/51 (0%)0/51 (0%)6/51 (11.8%)
INCB018424 1.5% BID0/259 (0%)0/259 (0%)23/259 (8.9%)
Most frequent serious events
Most frequent serious events
EventVehicle BIDTriamcinolone 0.1% BID for 4 Weeks Then 4 Week Vehicle BIDINCB018424 0.15% QDINCB018424 0.5% QDINCB018424 1.5% QDINCB018424 1.5% BID
Myocardial infarctionCardiac disorders0/521/510/510/510/510/259
Most frequent other events
Most frequent other events
EventVehicle BIDTriamcinolone 0.1% BID for 4 Weeks Then 4 Week Vehicle BIDINCB018424 0.15% QDINCB018424 0.5% QDINCB018424 1.5% QDINCB018424 1.5% BID
NasopharyngitisInfections and infestations4/520/513/511/514/5113/259
Dermatitis atopicSkin and subcutaneous tissue disorders4/522/511/510/512/514/259
Upper respiratory tract infectionInfections and infestations3/521/512/511/511/517/259

Baseline characteristics

Intent-to-Treat (ITT) population included all participants who are randomized to the study.

Age, Continuous
Age, Continuous(years)Double Blind (DB): Vehicle BIDDB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BIDDB: Ruxolitinib 0.15% Once Daily (QD)DB : Ruxolitinib 0.5% QDDB : Ruxolitinib 1.5% QDDB : Ruxolitinib 1.5% Cream Twice Daily (BID)Total
Mean34.8 ± 15.0438.5 ± 16.1938.4 ± 13.8338.6 ± 13.7339.1 ± 14.5439.0 ± 15.7238.1 ± 14.82
Sex: Female, Male
Sex: Female, Male(Participants)Double Blind (DB): Vehicle BIDDB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BIDDB: Ruxolitinib 0.15% Once Daily (QD)DB : Ruxolitinib 0.5% QDDB : Ruxolitinib 1.5% QDDB : Ruxolitinib 1.5% Cream Twice Daily (BID)Total
Female322826273124168
Male202325242126139
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double Blind (DB): Vehicle BIDDB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BIDDB: Ruxolitinib 0.15% Once Daily (QD)DB : Ruxolitinib 0.5% QDDB : Ruxolitinib 1.5% QDDB : Ruxolitinib 1.5% Cream Twice Daily (BID)Total
Hispanic or Latino38231320
Not Hispanic or Latino474349485147285
Other2000002
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double Blind (DB): Vehicle BIDDB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BIDDB: Ruxolitinib 0.15% Once Daily (QD)DB : Ruxolitinib 0.5% QDDB : Ruxolitinib 1.5% QDDB : Ruxolitinib 1.5% Cream Twice Daily (BID)Total
White/Caucasian272827332433172
Black/African-American15131710171385
Asian885810241
Native Hawaiian/Pacific Islander1000001
Other1220128
08

Study locations

52 sites
  • UAB DERMATOLOGY, 2000 6th Avenue South
    Birmingham, Alabama 35233, United States
  • BURKE PHARMACEUTICAL RESEARCH, 601 W. Commerce
    Bryant, Arkansas 72022, United States
  • ENCINO RESEARCH CENTER, 16133 Ventura Blvd
    Encino, California 91436, United States
  • DERMATOLOGY RESEARCH ASSOCIATES,8930 South Sepulveda Blvd
    Los Angeles, California 90045, United States
  • DERMATOLOGY SPECIALISTS, INC, 3629 Vista Way
    Oceanside, California 92056, United States
  • INTEGRATED RESEARCH GROUP, INC, 4646 Brockton Avenue
    Riverside, California 92506, United States
  • SAN LUIS DERMATOLOGY AND LASER CLINIC, 15 Santa Rosa Street
    San Luis Obispo, California 93405, United States
  • NEW ENGLAND RESEARCH ASSOCIATES LLC, 5520 Park Avenue
    Trumbull, Connecticut 06611, United States
  • DS RESEARCH, 2241 Green Valley Road
    New Albany, Indiana 47150, United States
  • THE INDIANA CLINICAL TRIALS CENTER, 824 Edwards Drive
    Plainfield, Indiana 46168, United States
  • DERMRESEARCH, 1169 Eastern Parkway 2310
    Louisville, Kentucky 40217, United States
  • DS RESEARCH, 3810 Springhurst Blvd
    Louisville, Kentucky 40241, United States
  • ACTIVMED PRACTICES & RESEARCH, INC, 138 Conant Street
    Beverly, Massachusetts 01915, United States
  • TUFTS MEDICAL CENTER, 800 Washington Street
    Boston, Massachusetts 02111, United States
  • HENRY FORD HOSPITAL, 3031 West Grand Blvd
    Detroit, Michigan 48202, United States
  • WASHINGTON UNIVERSITY - DERMATOLOGY, 4921 Parkview Place
    Saint Louis, Missouri 63110, United States
  • WASHINGTON UNIVERSITY - DERMATOLOGY, 969 Mason Road
    Saint Louis, Missouri 63141, United States
  • ACTIVMED PRACTICES AND RESEARCH, INC, 110 Corporate Drive
    Portsmouth, New Hampshire 03801, United States
  • HASSMAN RESEARCH INSTITUTE, LLC, 175 Cross Keys Road
    Berlin, New Jersey 08009, United States
  • DERMATOLOGY CONSULTING SERVICES, PLLC, 2444 North Main Street
    High Point, North Carolina 27262, United States
  • WAKE RESEARCH ASSOCIATES LLC, 3100 Duraleigh Road
    Raleigh, North Carolina 27612, United States
  • DERMATOLOGISTS OF GREATER COLUMBUS, 2359 East Main Street
    Bexley, Ohio 43209, United States
  • RAPID MEDICAL RESEARCH, INC, 3619 Park East Drive
    Cleveland, Ohio 44122, United States
  • CENTRAL SOONER RESEARCH, 900 North Porter
    Norman, Oklahoma 73071, United States
  • PARISH DERMATOLOGY, INC, 1845 Walnut Street
    Philadelphia, Pennsylvania 19103, United States
  • PEAK RESEARCH LLC, 2589 Washington Rd
    Upper Saint Clair, Pennsylvania 15241, United States
  • ARLINGTON RESEARCH CENTER, INC, 711 East Lamar Blvd
    Arlington, Texas 76011, United States
  • DERMRESEARCH INC., 8140 North Mopac Expressway
    Austin, Texas 78759, United States
  • J&S STUDIES, INC, 1710 Crescent Pointe Pkwy
    College Station, Texas 77845, United States
  • CENTER FOR CLINICAL STUDIES (CCS), 1401 Binz
    Houston, Texas 77004, United States
  • SUZANNE BRUCE AND ASSOCIATES, PA, 1900 St. James Place
    Houston, Texas 77056, United States
  • CLINICAL TRIALS OF TEXAS, INC, 7940 Floyd Curl Drive
    San Antonio, Texas 78229, United States
  • DERMATOLOGY CLINICAL RESEARCH CENTER OF SAN ANTONIO, 7810 Louis Pasteur
    San Antonio, Texas 78229, United States
  • CENTER FOR CLINICAL STUDIES, 451 North Texas Avenue
    Webster, Texas 77598, United States
  • CHARLOTTESVILLE DERMATOLOGY, 600 Peter Jefferson Parkway
    Charlottesville, Virginia 22911, United States
  • INSTITUTE FOR SKIN ADVANCEMENT, 4935 40th Avenue Nw
    Calgary, Alberta T3A 2N1, Canada
  • DR. CHIH-HO HONG MEDICAL INC., 15300 105 Avenue
    Surrey, British Columbia V3R 6A7, Canada
  • WISEMAN DERMATOLOGY RESEARCH INC, 6 - 1170 Taylor Avenue
    Winnipeg, Manitoba R3M 3Z4, Canada
  • CCA MEDICAL RESEARCH, 95 Bayly Street West
    Ajax, Ontario L1S 7K8, Canada
  • SIMCODERM MEDICAL AND SURGICAL DERMATOLOGY CENTER, 5 Quarry Ridge Road
    Barrie, Ontario L4M 7G1, Canada
  • LYNDERM RESEARCH INC, 25 Main Street Markham North
    Markham, Ontario L3P 1X2, Canada
  • DERMEDGE RESEARCH INC., 333 Lakeshore Road West
    Mississauga, Ontario L5H 1G9, Canada
  • NORTH BAY DERMATOLOGY CENTRE, 500 Cassells Street
    North Bay, Ontario P1B 3Z7, Canada
  • RESEARCH BY ICLS, 1344 Cornwall Road
    Oakville, Ontario L6J 7W5, Canada
  • OFFICE OF DR. MICHAEL ROBERN, 1 Centrepointe Drive
    Ottawa, Ontario K2G 6E2, Canada
  • SKIN CENTRE FOR DERMATOLOGY, 775 Monaghan Road
    Peterborough, Ontario K9J 5K2, Canada
  • YORK DERMATOLOGY CENTER, 250 Harding Blvd West
    Richmond Hill, Ontario L4C 9M7, Canada
  • RESEARCH TORONTO, 208 Bloor Street West
    Toronto, Ontario M5Sz 2B4, Canada
  • K. PAPP CLINICAL RESEARCH, 135 Union Street East
    Waterloo, Ontario N2J 1C4, Canada
  • XLR8 MEDICAL RESEARCH, 2425 Tecumseh Road East
    Windsor, Ontario N8W 1E6, Canada
  • WINDSOR CLINICAL RESEARCH INC, 2224 Walker Road
    Windsor, Ontario N8W 5L7, Canada
  • CLINIQUE DERMATOLOGIQUE DE SAINT-JEROME, 555 Boul. Saint-antoine
    Saint-jerome, Quebec J7Z 3B8, Canada
09

References and documents

Publications

  • Gong X, Chen X, Kuligowski ME, Liu X, Liu X, Cimino E, McGee R, Yeleswaram S. Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies. Am J Clin Dermatol. 2021 Jul;22(4):555-566. doi: 10.1007/s40257-021-00610-x. Epub 2021 May 12. PubMed 33982267 ↗
  • Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME; INCB 18424-206 Study Investigators. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020 Feb;145(2):572-582. doi: 10.1016/j.jaci.2019.08.042. Epub 2019 Oct 17. PubMed 31629805 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Jan 2018, 12 months.

Results were first posted in Apr 2021, 3 years 2 months after primary completion. A results delay was requested in Jan 2019.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 12 months is close to that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2017
First posted
Jan 5, 2017
StartActual
Jan 9, 2017
Primary completionActual
Jan 10, 2018
CompletionActual
Mar 12, 2018
Results delay requested
Jan 25, 2019
Results first posted
Apr 9, 2021
Last update
Apr 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03011892
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Jan 5, 2017
Start date
Jan 9, 2017
Primary completion
Jan 10, 2018
Completion
Mar 12, 2018
Results posted
Apr 9, 2021
Last update
Apr 9, 2021

Study contacts

Michael Kuligowski, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion